The estimated Net Worth of Gregory Bailey is at least $99.6 million dollars as of 13 May 2024. Gregory Bailey owns over 15,000 units of Biohaven Ltd stock worth over $57,690,336 and over the last 8 years he sold BHVN stock worth over $41,139,295. In addition, he makes $734,433 as Director at Biohaven Ltd.
Sign up
Gregory Bailey BHVN stock SEC Form 4 insiders trading
Gregory has made over 25 trades of the Biohaven Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of BHVN stock worth $512,850 on 13 May 2024.
The largest trade he's ever made was exercising 438,200 units of Biohaven Ltd stock on 5 June 2020 worth over $2,055,158. On average, Gregory trades about 52,112 units every 73 days since 2017. As of 13 May 2024 he still owns at least 1,615,071 units of Biohaven Ltd stock.
You can see the complete history of Gregory Bailey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gregory Bailey biography
Dr. Gregory H. Bailey, M.D., serves as Director of the Company. Dr. Bailey has served as a director of our Company since January 2014. Since co-founding the company in October 2016, Dr. Bailey has served as CEO of Juvenescence Limited, a life science and biotech company developing therapies to increase healthy human longevity. Dr. Bailey is a co-founder and has served as managing partner of MediqVentures since January 2014, the chairman and director of Portage Biotech, Inc. (OTCBB: PTGEF) since June 2013, a director of Portage Pharmaceuticals Limited since June 2013, and director of Manx Financial Group since March 2018. He has been a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings since April 2002. Dr. Bailey was a founder of SalvaRx Group Plc (LSE: SALV) and has served on its board of directors since May 2015. Dr. Bailey was also the co-founder of Ascent Healthcare Solutions, VirnetX Inc. (AMEX:VHC), Portage Biotech Inc. and DuraMedic Inc. He was the initial financier and an independent director of Medivation, Inc. (NASDAQ: MDVN), from 2005 to December 2012. Dr. Bailey practiced emergency medicine for ten years before entering finance. He received his medical degree from the University of Western Ontario. Bailey’s extensive venture capital industry experience and technical background, along with his experience with public companies and biopharmaceutical companies, qualifies him to serve as a member of our Board.
What is the salary of Gregory Bailey?
As the Director of Biohaven Ltd, the total compensation of Gregory Bailey at Biohaven Ltd is $734,433. There are 10 executives at Biohaven Ltd getting paid more, with Vlad Coric having the highest compensation of $6,787,630.
How old is Gregory Bailey?
Gregory Bailey is 64, he's been the Director of Biohaven Ltd since 2014. There are 1 older and 14 younger executives at Biohaven Ltd. The oldest executive at Biohaven Ltd is Julia Gregory, 67, who is the Independent Director.
What's Gregory Bailey's mailing address?
Gregory's mailing address filed with the SEC is C/O BIOHAVEN LTD., 215 CHURCH STREET, NEW HAVEN, CT, 06510.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs et Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Gregory Bailey stock trades at Biohaven Ltd et AgeX Therapeutics Inc
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer